TY - JOUR
T1 - Effects of prostaglandin E1α cyclodestrin treatment on endothelial dysfunction in patients with systemic sclerosis
AU - Giannattasio, Cristina
AU - Pozzi, MariaRosa
AU - Gradinali, Marco
AU - Montemerlo, Elisabetta
AU - Citterio, Francesca
AU - Maestroni, Silvia
AU - Fantini, Elena
AU - Failla, Monica
AU - Robuschi, Maria
AU - Bianco, Salvatore
AU - Mancia, Giuseppe
PY - 2007/4
Y1 - 2007/4
N2 - OBJECTIVE: Systemic sclerosis (SSc) is characterized by an altered nitric oxide (NO): endothelin I ratio and by endothelial dysfunction. AIMS: To verify the effects of prostaglandin E1 (PGE1) α-cyclodestrin treatment on endothelial function, quantified as flow-mediated dilation (FMD) of the radial artery. METHODS: In 16 women with SSc (age 57 ± 2.7 years, means ± SE) in whom a diagnosis of SSc had been made several years earlier (7.1 ± 1.2 years), FMD was evaluated by an echotracking technique on the radial artery, using trinitroglycerin vasodilation as a non-endothelial measure of the vessel's ability to increase its diameter maximally. FMD was evaluated after 4 months washout period and after 4 months cyclic infusion of PGE1 α-cyclodestrin. Expired NO was measured at the same time. RESULTS: PGE1 α-cyclodestrin cyclic infusions did not modify systolic and diastolic blood pressure, heart rate or trinitroglycerin radial artery vasodilation. On the other hand, it induced a marked and significant increase in FMD of the radial artery, which was also accompanied by an increase in blood flow and expired NO. CONCLUSIONS: Endothelial dysfunction and reduced FMD associated with SSc are improved by cyclic treatment with PGE1 α-cyclodestrin. This effect occurs together with a concomitant increase in expired NO, suggesting its direct positive influence on endothelial function. It may also partly explain the clinical beneficial effect of the drug in SSc.
AB - OBJECTIVE: Systemic sclerosis (SSc) is characterized by an altered nitric oxide (NO): endothelin I ratio and by endothelial dysfunction. AIMS: To verify the effects of prostaglandin E1 (PGE1) α-cyclodestrin treatment on endothelial function, quantified as flow-mediated dilation (FMD) of the radial artery. METHODS: In 16 women with SSc (age 57 ± 2.7 years, means ± SE) in whom a diagnosis of SSc had been made several years earlier (7.1 ± 1.2 years), FMD was evaluated by an echotracking technique on the radial artery, using trinitroglycerin vasodilation as a non-endothelial measure of the vessel's ability to increase its diameter maximally. FMD was evaluated after 4 months washout period and after 4 months cyclic infusion of PGE1 α-cyclodestrin. Expired NO was measured at the same time. RESULTS: PGE1 α-cyclodestrin cyclic infusions did not modify systolic and diastolic blood pressure, heart rate or trinitroglycerin radial artery vasodilation. On the other hand, it induced a marked and significant increase in FMD of the radial artery, which was also accompanied by an increase in blood flow and expired NO. CONCLUSIONS: Endothelial dysfunction and reduced FMD associated with SSc are improved by cyclic treatment with PGE1 α-cyclodestrin. This effect occurs together with a concomitant increase in expired NO, suggesting its direct positive influence on endothelial function. It may also partly explain the clinical beneficial effect of the drug in SSc.
KW - Alfa 1 cycodestrin
KW - Arterial vessel
KW - Endothelium
KW - Raynaud disease
KW - Systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=33947184833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947184833&partnerID=8YFLogxK
U2 - 10.1097/HJH.0b013e328032784f
DO - 10.1097/HJH.0b013e328032784f
M3 - Article
C2 - 17351371
AN - SCOPUS:33947184833
VL - 25
SP - 793
EP - 797
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 4
ER -